Research programme: CX 3000 series - Cylene

Drug Profile

Research programme: CX 3000 series - Cylene

Alternative Names: CX 3000 series research programme - Cyternex

Latest Information Update: 24 Dec 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cylene Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 01 Jan 2013 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 15 Oct 2003 Cyternex is now called Cylene Pharmaceuticals
  • 02 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top